NTRK1 and pachyonychia congenita: These findings, together with the observation that Receptor Tyrosine Kinase (RTK) inhibitors frequently induce side effects and resistance ([29,35], and therein refs) indicate that only a precise understanding of the molecular landscape in human PC specimens might allow a more tailored therapy.